Eco Animal Health Group PLC
EAH.L is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of prescription drugs and related healthcare products.
Business. EAH.L is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm operates within the broader healthcare sector, specifically focusing on pharmaceuticals and medical research activities. It is primarily listed on the London Stock Exchange under the ticker symbol EAH.L. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
Analyst recommendations
4 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
EAH.L is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm operates within the broader healthcare sector, specifically focusing on pharmaceuticals and medical research activities. It is primarily listed on the London Stock Exchange under the ticker symbol EAH.L. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
EAH.L maintains a strong liquidity position, with GBP 25.006 million in cash and equivalents, and a current ratio of 3.21, indicating the company can easily cover its short-term liabilities. The company's debt-to-equity ratio is 0.04, suggesting a conservative capital structure with minimal reliance on debt financing. However, the company reported negative free cash flow of GBP -0.604 million, which may signal pressure on cash generation despite positive operating cash flow of GBP 10.448 million.
In terms of profitability, EAH.L's return on equity (ROE) is 1.97%, and return on assets (ROA) is 1.4%, both of which are below the typical thresholds for high-performing pharmaceutical firms. These metrics suggest the company is not generating strong returns relative to its equity and asset base. The operating margin is 5.41% (calculated from operating income of GBP 4.301 million on revenue of GBP 79.596 million), which is modest compared to industry benchmarks.
The company's revenue is not segmented by product or geographic region in the available data, making it difficult to assess the concentration of earnings or exposure to specific markets. However, the lack of geographic breakdown may indicate a relatively diversified or global presence, or it may reflect limited disclosure.
Looking ahead, EAH.L's growth trajectory is not clearly defined in the available data. The company's revenue for the latest period is GBP 79.596 million, but there is no provided outlook for the current or next fiscal year. Analysts have assigned a mean price target of GBP 195.75, with a median of GBP 175.00, suggesting a generally positive sentiment, though not overwhelmingly bullish.
Risk factors for EAH.L are currently assessed as low for both liquidity and dilution. The company has no immediate filing-based liquidity or dilution flags, and its capital structure remains stable with low leverage. However, the negative free cash flow could be a concern if it persists, as it may limit the company's ability to invest in growth or return capital to shareholders.
Recent events and filings do not show any material changes or disclosures that would significantly impact the company's operations or financial position. The absence of recent earnings calls or major announcements suggests a stable but potentially uneventful period for EAH.L.
- EAH.L has a strong liquidity position with GBP 25.006 million in cash and a current ratio of 3.21.
- The company's ROE and ROA are below typical benchmarks for pharmaceutical firms, indicating suboptimal returns.
- Free cash flow is negative, which may signal pressure on cash generation despite positive operating cash flow.
- Analysts have a generally positive outlook, with a mean price target of GBP 195.75.
- No immediate liquidity or dilution risks are flagged, but the negative free cash flow could be a concern if it continues.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,03 |
| Revenue | —no estimate | —no estimate | 85,9M GBP |
| Operating income | —no estimate | —no estimate | 5,2M GBP |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- EAH.L Market data — financials · 2026-05-27
- ECO Animal Health Group PLC Market data — analyst estimates · 2026-05-27
Ownership & reference
Leadership
- David Charles HallasChief Executive Officer, Executive Director